Octreotide With Pantoprazole (Protonix)
Coadministration of octreotide with pantoprazole is not expected to cause a clinically important direct drug-drug interaction based on available U.S. prescribing information. [1], [2]
Interaction Evidence
Octreotide (Sandostatin injection) labeling lists several clinically relevant drug interactions, including effects on CYP3A4-metabolized drugs with a low therapeutic index, but does not identify pantoprazole as an interacting medication. [1]
Pantoprazole (Protonix) labeling states that no significant drug-drug interactions were observed in clinical studies for multiple coadministered drugs, but it does not specifically name octreotide among interaction statements. [2]
Route-Specific Considerations for Octreotide Products
Octreotide injection (Sandostatin)
- No pantoprazole-specific interaction or dose adjustment is specified in Sandostatin injection labeling. [1]
Oral octreotide capsules (MYCAPSSA)
- Proton pump inhibitors (including pantoprazole) may decrease MYCAPSSA bioavailability. [3]
- Concomitant use of proton pump inhibitors may require increased MYCAPSSA dosage. [3]
- Esomeprazole coadministration data show reduced MYCAPSSA exposure (mean AUC ratio 0.59) consistent with PPI-related reductions in absorption. [3]
Special Dosing and Monitoring Considerations
Octreotide can alter glucose homeostasis. [1], [3]
- Glucose monitoring is recommended during octreotide therapy, especially when treatment is initiated or the dose is changed (risk of hypoglycemia or hyperglycemia). [3]
Octreotide can cause bradycardia. [3]
- Concomitant bradycardia-effect drugs may require dose adjustments (pantoprazole is not specifically highlighted for this issue). [3]
Octreotide can cause gallbladder dysfunction. [3]
- Periodic monitoring for gallbladder-related adverse reactions is recommended. [3]
CYP3A4 and Other Medication Interaction Risks to Review
Octreotide labeling indicates caution with drugs mainly metabolized by CYP3A4 that have a low therapeutic index (examples include quinidine and terfenadine). [1]
Pantoprazole labeling supports that it does not significantly affect the pharmacokinetics of multiple listed drugs, including several CYP-related and transported drugs, and it also notes limited interaction concerns in the studied settings. [2]
Practical Coadministration Summary
If octreotide is being administered as an injection, no pantoprazole-specific interaction management is indicated by labeling. [1]
If octreotide is being administered as oral MYCAPSSA, pantoprazole can reduce MYCAPSSA bioavailability, and dose adjustment may be required with monitoring for disease control. [3]
Octreotide and pantoprazole can generally be coadministered with routine clinical monitoring for octreotide adverse effects (glucose abnormalities, bradycardia, and gallbladder events). [1], [3]